CPI has signed an agreement with PwC, making it a partner in the Medicines Manufacturing Innovation Centre collaboration. The partnership will leverage PwC’s global reach, expertise and experience within the life sciences sector to drive economic growth and help advance medicines manufacturing innovations in the UK.

PwC will join founding partners CPI, the University of Strathclyde, GSK and AstraZeneca to address challenges and maximize technology opportunities in the pharmaceutical supply chain. The flagship ‘Grand Challenge’ projects, are working to advance emergent and disruptive technologies. The program is part-funded by Innovate UK through the Industrial Strategy Challenge Fund and Scottish Enterprise via the Scottish Government.

PwC will increase opportunities for business development and will evaluate the marketplace for future technologies, acting as a scout for new disruptive innovations, organizations and global opportunities. PwC will also develop market analysis and studies to communicate the value of current and future projects and demonstrate impact while helping to seek funding from private investors, industry and government.

Johnathon Marshall, UK Pharma and Life Science Consulting lead at PwC, said: “We are excited to join the team at the Medicines Manufacturing Innovation Centre – bringing PwC’s insights, experiences and connections. We are confident that this collaboration will have a big impact on the future of pharmaceutical manufacturing.”

Dave Tudor, Managing Director of the Medicines Manufacturing Innovation Centre, Biologics & Quality at CPI, said: “By partnering with PwC, the Medicines Manufacturing Innovation Centre will be able to work smarter, better and faster, ensuring more value to patients and the economy while advancing the UK’s already strong medicines manufacturing industry even further.”